Filing Flows › Madrigal Pharmaceuticals (MDGL) › Q1 2025
Madrigal Pharmaceuticals (MDGL) Q1 2025 earnings results (first quarter 2025)
10-Q filed May 1, 2025
Madrigal Pharmaceuticals (MDGL) reported revenue of $137M for the first quarter 2025 (Q1 2025) and +33% from the quarter before. Operating margin was -57.8%, net loss $73.2M (53.4% of revenue).
Madrigal Pharmaceuticals, Q1 2025: revenue $137M, operating margin -57.8%, net loss $73.2M, operating cash flow −$88.9M. The chart follows the revenue to costs, profit and cash.
| Q1 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $137M | +33% | — |
| Operating profit | −$79.3M | — | — |
| Net earnings | −$73.2M | — | — |
| Operating cash flow | −$88.9M | — | — |
What changed
Revenue was $137.2M in Q1 2025, up 33% from the previous quarter.
Operating costs exceeded revenue by $79.3M, an operating margin of -57.8%. The quarter ended with a net loss of $73.2M, wider than the previous quarter's $59.4M loss.
Operating cash flow was −$88.9M. Non-cash charges added back $379K of depreciation and amortization and $20.9M of share-based compensation. Working capital and other items used $37.0M.
Questions
What was Madrigal Pharmaceuticals' revenue in the first quarter 2025?
Madrigal Pharmaceuticals (MDGL) reported revenue of $137M for the first quarter 2025 (Q1 2025) and +33% from the quarter before.
Was Madrigal Pharmaceuticals profitable in the first quarter 2025?
Operating loss was $79.3M (-57.8% of revenue) and net loss $73.2M.